| Abstrakt: |
Researchers at Semmelweis University in Budapest, Hungary have conducted a study on miRNA-based therapy for schizophrenia. The study found that a specific non-coding polymorphism in the glial cell line-derived neurotrophic factor (GDNF) gene, known as rs11111, was associated with schizophrenia. In vitro experiments showed that this polymorphism created binding sites for certain microRNA (miRNA) species, which led to the downregulation of GDNF expression. These findings suggest that the rs11111 polymorphism may play a role in the pathogenesis of schizophrenia and could potentially be targeted for therapeutic interventions. [Extracted from the article] |
